ClinicalTrials.gg
Sign In

Drug

QLS4131 clinical trials

Also written QLS4131.

studies test it
5
open now
5
in phase 3
0
first study started
2024

Keep track of what changes. Save the QLS4131 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

QLS4131
3

Studies by the year they started

5 studies that test it; most in 2026 (3)

Studies that test QLS4131, by start year
YearStudies
20241
20251
20263

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
3

What it is tested for

Each study’s main condition, where its own words name it.

Multiple Myeloma
2
Immunoglobulin Light-chain Amyloidosis
1
Lupus Erythematosus, Systemic
1

Who runs them

Industry 2 · Other 3

Institute of Hematology & Blood Diseases Hospital, China (3) · Qilu Pharmaceutical Co., Ltd. (2)

Studies

Open first, then newest update. How each study uses QLS4131 is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 5

Given beside what is tested · 1 — QLS4131 is usual care or a partner of the new treatment